Health News

Inflammatory Disease Rx Gets Green Light
The US Food and Drug Administration (FDA) has approved a new medication to treat multiple chronic inflammatory diseases.
Another Biosimilar Gets a Green Light
The US Food and Drug Administration (FDA) has approved another biosimilar. This one is meant to treat multiple conditions that affect the immune system.
Green Light for Biosimilar to Humira
The US Food and Drug Administration has approved its fourth biosimilar.
FDA Approves First Biosimilar Etanercept
The US Food and Drug Administration (FDA) has approved the first biosimilar etanercept. 
Are 'Generic' Biologics the Same as the 'Brand'?
Generic versions of often expensive brand-name biologic medications appear safe and effective on the whole, a new study found.
Second Biosimilar Gets FDA Nod
The US Food and Drug Administration (FDA) has approved the second-ever biosimilar, and it's meant to treat multiple conditions that affect the immune system.
Understanding Autoimmune Disorders
A healthy and functioning immune system is central to your body’s ability to protect itself from bacteria, viruses, toxins and even cancerous cells. Unfortunately, it is possible for the immune system to go overboard when trying to protect the body.
Famous People with Arthritis
Arthritis is a broad term that describes a variety of conditions that affect muscles, bones and joints. Here are some famous people who have had to battle arthritis.
How Do You Know if You Have Arthritis?
How do you know if you have arthritis? What exactly are the symptoms of arthritis? dailyRx has set out to answer these questions, along with several others. Learn how arthritis can impact your overall health, and listen to your body so that you can get treatment as soon as possible.
Long-Term Effects of Golimumab in Patients with Arthritis
Clinicians are generally familiar with the side effects of most prescribed medications. However, the safety of newer medications such as golimumab, an anti-TNF drug to treat autoimmune disorders, is still being examined.